Principles of Hematopoietic Stem Cell Transplantation

  • Michelle Limei Poon
  • Richard E. Champlin
  • Partow KebriaeiEmail author


Hematopoietic stem cell transplantation (HSCT) refers to the process of intravenous infusion of self-renewing hematopoietic stem cells to restore normal hematopoiesis and is a rapidly developing and highly effective modality of treatment for a wide range of immunologic, metabolic, hematologic, as well as malignant diseases. Patients undergoing HSCT are at high risk of infectious complications in the peri-transplant period while awaiting immune reconstitution. There has been significant progress in this field, with improved supportive care, as well as development of novel reduced-intensity preparative regimens all of which have markedly reduced toxicities associated with this procedure and improved treatment outcomes. In addition, the use of alternative donor grafts, such as umbilical cord and haploidentical donors, allows more patients to have access to HSCT. This chapter aims to provide a broad overview of HSCT, reviewing both the historical aspects and the underlying immunobiology of this procedure. In addition, technical aspects of HSCT, latest advances in the field and an overview of the relevant literature, and clinical issues faced in practice are also discussed.


Autologous Allogeneic hematopoietic stem cell transplantation 


  1. 1.
    National marrow donor program website
  2. 2.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–62.PubMedGoogle Scholar
  3. 3.
    Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433–44.PubMedCrossRefGoogle Scholar
  4. 4.
    Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–5.PubMedGoogle Scholar
  5. 5.
    Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–50.PubMedGoogle Scholar
  6. 6.
    Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330(2):100–6.PubMedCrossRefGoogle Scholar
  7. 7.
    van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondón G, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19(10):977–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26(5):511–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Osgood E. Aplastic anemia treated with daily transfusions and intravenous marrow: case report. Ann Intern Med. 1939;13:357–67.CrossRefGoogle Scholar
  10. 10.
    Jacobson LO, Simmons EL, Marks EK, Robson MJ, Bethard WF, Gaston EO. The role of the spleen in radiation injury and recovery. J Lab Clin Med. 1950;35(5):746–70.PubMedGoogle Scholar
  11. 11.
    Jacobson LO, Simmons EL, Bethard WF. Studies on hematopoietic recovery from radiation injury. J Clin Invest. 1950;29(6):825.PubMedGoogle Scholar
  12. 12.
    Storb R, Epstein RB, Bryant J, Ragde H, Thomas ED. Marrow grafts by combined marrow and leukocyte infusions in unrelated dogs selected by histocompatibility typing. Transplantation. 1968;6(4):587–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation. 1970;9(3):240–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Storb R, Rudolph RH, Thomas ED. Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. J Clin Invest. 1971;50(6):1272–5.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 1968;2(7583):1364–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2(7583):1366–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M, Devries MJ, et al. Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemic effects. Blood. 1965;25:179–96.PubMedGoogle Scholar
  18. 18.
    Champlin RE, Kastenberg WE, Gale RP. Radiation accidents and nuclear energy: medical consequences and therapy. Ann Intern Med. 1988;109(9):730–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328(9):593–602.PubMedCrossRefGoogle Scholar
  21. 21.
    Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339(22):1565–77.PubMedCrossRefGoogle Scholar
  22. 22.
    Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24(36):5695–702.PubMedCrossRefGoogle Scholar
  24. 24.
    Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood. 1997;90(12):4665–78.PubMedGoogle Scholar
  26. 26.
    Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342(25):1846–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–60.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;8(7):368–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Robinson SN, Simmons PJ, Yang H, Alousi AM, Marcos de Lima J, Shpall EJ. Mesenchymal stem cells in ex vivo cord blood expansion. Best Pract Res Clin Haematol. 2011;24(1):83–92.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438–45.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–9.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197–204.PubMedCrossRefGoogle Scholar
  34. 34.
    Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990;29(2):79–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–71.PubMedCrossRefGoogle Scholar
  36. 36.
    Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948–55.PubMedGoogle Scholar
  37. 37.
    Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447–54.PubMedCrossRefGoogle Scholar
  38. 38.
    Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–64.PubMedCrossRefGoogle Scholar
  39. 39.
    Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–86.PubMedCrossRefGoogle Scholar
  41. 41.
    Champlin RE. Peripheral blood progenitor cells: a replacement for marrow transplantation? Semin Oncol. 1996;23(2 Suppl 4):15–21.PubMedGoogle Scholar
  42. 42.
    Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells. 1997;15(1):9–17.PubMedCrossRefGoogle Scholar
  43. 43.
    Körbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86(7):2842–8.PubMedGoogle Scholar
  44. 44.
    Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18(3):537–46.PubMedCrossRefGoogle Scholar
  46. 46.
    Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525–31.PubMedCrossRefGoogle Scholar
  47. 47.
    Heldal D, Tjønnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25(11):1129–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Mahmoud F, Abul H, al-Seleh Q, Morgan G, Haines D, al-Ramly M, et al. Differential expression of interferon gamma by mitogen-stimulated peripheral blood mononuclear cells among Kuwaiti psoriasis patients. J Dermatol. 1999;26(1):23–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355(9211):1231–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Schmitz N, Beksar M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100(3):761–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22(12):1145–51.PubMedCrossRefGoogle Scholar
  52. 52.
    Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074–87.PubMedCentralCrossRefGoogle Scholar
  53. 53.
    Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397–400.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. ASH Ann Meet Abstr. 2011;118(21):1.Google Scholar
  55. 55.
    Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6.PubMedGoogle Scholar
  56. 56.
    Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63.PubMedGoogle Scholar
  57. 57.
    Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667–74.PubMedCrossRefGoogle Scholar
  59. 59.
    Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996;88(11):4383–9.PubMedGoogle Scholar
  60. 60.
    Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood. 1992;80(2):560–1.PubMedGoogle Scholar
  61. 61.
    Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76(8):1464–72.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Michelle Limei Poon
    • 1
  • Richard E. Champlin
    • 2
  • Partow Kebriaei
    • 2
    Email author
  1. 1.National University Hospital, Department of Hematology OncologySingaporeSingapore
  2. 2.MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular TherapyHoustonUSA

Personalised recommendations